3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
46
Carcinoma, Hepatocellular
13
Osteosarcoma
8
Neoplasms
8
Sarcoma
7
Prostatic Neoplasms
7
Neoplasm Metastasis
7
Colorectal Neoplasms
7
Sarcoma, Ewing
6
Neuroendocrine Tumors
6
Kidney Neoplasms
6
Clear-cell metastatic renal cell carcinoma
6
Carcinoma, Non-Small-Cell Lung
6
Thyroid Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Medullary
4
Carcinoma
4
Brain Neoplasms
4
Urinary Bladder Neoplasms
3
Urethral Neoplasms
3
Ovarian Neoplasms
3
Melanoma
3
Endometrial Neoplasms
3
Adrenocortical Carcinoma
3
Wilms Tumor
2
Urogenital Neoplasms
2
Ureteral Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Cancer, Papillary
2
Stomach Neoplasms
2
Interventions
Cisplatin
15
Pemetrexed
12
pembrolizumab
9
Carboplatin
8
Nivolumab
7
Platinum
6
Cyclophosphamide
6
Ipilimumab
5
1,2-diaminocyclohexaneplatinum II citrate
5
fludarabine
3
atezolizumab
3
Radiotherapy, Intensity-Modulated
3
Interleukin-2
3
Gemcitabine
3
tremelimumab
2
durvalumab
2
aldesleukin
2
Radiotherapy
2
Radiation
2
Photochemotherapy
2
Pharmaceutical Preparations
2
Methotrexate
2
Drug Therapy
2
Chemotherapy, Adjuvant
2
Cerebral Decortication
2
nintedanib
1
methoxyamine
1
decitabine and cedazuridine drug combination
1
cemiplimab
1
cediranib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
cabozantinib
×
1 year
×
Clear all
No trials found.